Abstract 603P
Background
Glioblastoma is a malignant brain tumour with a high recurrence rate following stanadard first-line treatment. While there are currently guidelines from NICE and EANO on the postoperative surveillance intervals for these patients, they were not evidence-based, and the quality of such recommendations remains untested. We therefore set out to provide an evidence-based recommendation on the optimal postoperative radiological surveillance schedule for glioblastoma patients after surgical treatment, tailored based on the extent of surgical resection and completion of adjuvant treatment.
Methods
This was a territory-wide, multicentre retrospective analysis of consecutive adult patients with IDH-wildtype glioblastoma treated with surgery and radiotherapy (RT) across seven neurosurgical units in Hong Kong between 2006-2020 (n=228). Data were extracted from the Hong Kong Glioblastoma Registry (HK-GBM Registry). Interval-censored Kaplan-Meier curves were constructed for the stratified groups based on the event-free survival of included patients, defined as time from the start date of RT to the occurrence of any event (tumour progression or death). A piecewise exponential model with different hazard functions in predefined time intervals was used to describe each curve. Accordingly, adopting a 15% event rate criterion, we generated the surveillance schedules.
Results
For a 15% event yield each scan (15% event rate criterion), we propose that glioblastoma patients treated with gross total resection be monitored with MRIs around every 9 weeks until 86 weeks after starting RT. Meanwhile, patients with residual tumour after surgery should be monitored more frequently at every 7 weeks until 75 weeks after RT initiation; and the interval should be further shortened to every 4 weeks for patients who were unable to complete the standard 6-weeks concurrent chemoradiotherapy.
Conclusions
Radiological surveillance is an important tool to detect postoperative tumour progression. The extent of surgical resection and completion of adjuvant treatment are major factors associated with glioblastoma progression and the frequency of radiological surveillance should therefore be guided by these two factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong Neuro-oncology Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract